Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Dow
Express Scripts
Harvard Business School
AstraZeneca
Boehringer Ingelheim
Colorcon

Last Updated: January 25, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for TAK-733

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the development status for investigational drug TAK-733?

TAK-733 is an investigational drug.

There have been 320 clinical trials for TAK-733. The most recent clinical trial was a Phase 3 trial, which was initiated on January 1st 2018.

The most common disease conditions in clinical trials are Diabetes Mellitus, Hypertension, and Diabetes Mellitus, Type 2. The leading clinical trial sponsors are Takeda, Millennium Pharmaceuticals, Inc., and National Cancer Institute (NCI).

There are thirty-eight US patents protecting this investigational drug and three hundred and fifty-five international patents.

Recent Clinical Trials for TAK-733
TitleSponsorPhase
A Pharmacokinetic and Safety Study of TAK-925 in Participants With Idiopathic HypersomniaMillennium Pharmaceuticals, Inc.Phase 1
A Study to Evaluate the Efficacy and Safety of Bismuth-Containing Quadruple Therapy With Oral Vonoprazan (TAK-438) 20 mg Compared to Esomeprazole 20 mg Twice Daily in Paticipants With Helicobacter Pylori InfectionTakedaPhase 3
A Study of TAK-994 in Participants With Narcolepsy Type 1TakedaPhase 1

See all TAK-733 clinical trials

Clinical Trial Summary for TAK-733

Top disease conditions for TAK-733
Top clinical trial sponsors for TAK-733

See all TAK-733 clinical trials

US Patents for TAK-733

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
TAK-733   Start Trial Antibody drug conjugates Novartis AG (Basel, CH)   Start Trial
TAK-733   Start Trial Compositions and methods for epithelial stem cell expansion and culture Massachusetts Institute of Technology (Cambridge, MA) The Brigham and Women's Hospital, Inc. (Boston, MA)   Start Trial
TAK-733   Start Trial Compositions and methods for epithelial stem cell expansion and culture Massachusetts Institute of Technology (Cambridge, MA) The Brigham and Women's Hospital, Inc. (Boston, MA)   Start Trial
TAK-733   Start Trial Antibody drug conjugates Novartis AG (Basel, CH)   Start Trial
TAK-733   Start Trial Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same Infinity Pharmaceuticals, Inc. (Cambridge, MA)   Start Trial
TAK-733   Start Trial Formylated N-heterocyclic derivatives as FGFR4 inhibitors NOVARTIS AG (Basel, CH)   Start Trial
TAK-733   Start Trial Triazolopyrimidine compounds and uses thereof Novartis AG (Basel, CH)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for TAK-733

Drugname Country Document Number Estimated Expiration Related US Patent
TAK-733 Argentina 102649 2034-11-14   Start Trial
TAK-733 Australia 2015347015 2034-11-14   Start Trial
TAK-733 Brazil 112017009813 2034-11-14   Start Trial
TAK-733 Canada 2967188 2034-11-14   Start Trial
TAK-733 Chile 2017001217 2034-11-14   Start Trial
TAK-733 China 108064244 2034-11-14   Start Trial
TAK-733 Costa Rica 20170200 2034-11-14   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Baxter
Moodys
McKinsey
Express Scripts
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.